None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Voluntarily decides to participate in this clinical study and signs the informed consent 2) Men and women aged 19 to 75 years inclusive at the time of signing the informed consent 3) upper limit of normal (ULN) < ALT or AST = 5 x upper limit of normal (ULN)
Exclusion criteria
Exclusion criteria: 1) A history of significant alcohol abuse or chronic alcoholic consumption 2) Viral liver disease and other liver diseases that may affect the results 3) Regularly intake of probiotics, prebiotics, synbiotics, fermented milk products within 4 weeks before screening visit 4) Use of drugs historically associated with hepatic steatosis 5) Use of drugs for the treatment of NAFLD or NASH within 3 months prior to screening, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of aminotransferase(AST, ALT) levels | — |
Secondary
| Measure | Time frame |
|---|---|
| Chang of liver function, lipid, glucose, HbA1c, cytokine, fatigue severity scale | — |
Countries
Korea, Republic of
Contacts
Hallym University Medical Center- Chuncheon